Appropriateness and limitations of modified Response Evaluation Criteria in Solid Tumors (mRECIST) in evaluating the efficacy of molecular-targeted therapy for patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

Appropriateness and limitations of modified Response Evaluation Criteria in Solid Tumors (mRECIST) in evaluating the efficacy of molecular-targeted therapy for patients with hepatocellular carcinoma

Published:2012 Issue:3 Volume:53 Page:147-154
ISSN:0451-4203
Container-title:Kanzo
language:ja
Short-container-title:Kanzo

Author:

Takeda Haruhiko,Osaki Yukio,Inuzuka Tadashi,Nakajima Jun,Matsuda Fumihiro,Sakamoto Azusa,Hatamaru Keiichi,Henmi Shinichiro,Ishikawa Tetsuro,Saito Sumio,Nishikawa Hiroki,Kita Ryuichi,Kimura Toru

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/53/3/53_3_147/_pdf

Reference13 articles.

1. 1) Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 2000; 92 (3): 205-216

2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

3. Response Evaluation of Gastrointestinal Stromal Tumors

4. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

5. High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment—Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement;European Radiology;2015-05-21

2. A case of hepatocellular carcinoma treated sorafenib therapy showing interesting clinical course about treatment interruption;Kanzo;2012